Search

Kevin M Guckian

from Northborough, MA
Age ~50
Get Report
Also known as:
Kevin Micheal Guckian, Kevin Miche Guckian, Kevin N
Phone and address:
44 Little Pond Rd, Northborough, MA 01532
(508) 466-8434
Related to:
Keath B Guckian, 27
Connected to:
Katherine F Guckian, 43Lana S Guckian, 57Lindsay A Guckian, 38Seth Guckian, 35Thomas F Guckian, 83Robert S Guckiean, 49Matthew J Guckin, 53Stephen A Guckin, 64Monica Gucu, 46Kent W Gucwa, 38

Kevin Guckian Phones & Addresses

  • 44 Little Pond Rd, Northborough, MA 01532 (508) 466-8434
  • 51 Violetwood Cir, Marlborough, MA 01752 (508) 485-7560
  • 4223 Evergreen Dr, Wilmington, MA 01887 (978) 657-4603
  • 3737 Nobel Dr, San Diego, CA 92122 (858) 535-1272
  • Victor, NY
  • Boston, MA
  • Rochester, NY

Work

Company: Biogen Jan 1, 2002 Position: Medicinal chemist at biogen idec

Education

School / High School: University of Rochester 1995 to 2000

Industries

Pharmaceuticals

Resumes

Resumes

Kevin Guckian Photo 1

Medicinal Chemist At Biogen Idec

View page
Location:
115 Broadway, Cambridge, MA 02142
Industry:
Pharmaceuticals
Work:
Biogen
Medicinal Chemist at Biogen Idec
The Scripps Research Institute 2000 - 2002
Postdoc
Education:
University of Rochester 1995 - 2000

Publications

Us Patents

Indazole Derivatives As Modulators Of Interleukin-1 Receptor-Associated Kinase

View page
US Patent:
8293923, Oct 23, 2012
Filed:
Sep 7, 2007
Appl. No.:
12/440163
Inventors:
Kevin Guckian - Marlborough MA, US
Charles Jewell - Sudbury MA, US
Patrick Conlon - Wakefield MA, US
Edward Yin Shiang Lin - Chestnut Hill MA, US
Timothy Chan - Newton MA, US
Assignee:
Biogen Idec MA Inc. - Cambridge MA
International Classification:
A61K 31/4188
A61K 31/5355
C07D 401/14
C07D 403/12
US Classification:
5483051, 5142315, 51425309, 514318, 514338, 514387, 544124, 544364, 546194, 5462734
Abstract:
The present invention relates to modulators of IRAK kinases of formula (I) and provides compositions comprising such modulators, as well as methods therewith for treating IRAK-mediated or IRAK-associated conditions or diseases.

Bicyclic Aryl Sphingosine 1-Phosphate Analogs

View page
US Patent:
8269043, Sep 18, 2012
Filed:
Oct 30, 2009
Appl. No.:
12/588883
Inventors:
Richard D. Caldwell - Somerville MA, US
Kevin M. Guckian - Marlborough MA, US
Gnanasambandam Kumaravel - Westford MA, US
Edward Yin-Shiang Lin - Chestnut Hill MA, US
Xiaogao Liu - Dover MA, US
Bin Ma - Arlington MA, US
Daniel M. Scott - Weston MA, US
Zhan Shi - Concord MA, US
Jermaine Thomas - Chelsea MA, US
Arthur G. Taveras - Southborough MA, US
Guo Zhu Zheng - Lexington MA, US
Assignee:
Biogen Idec MA Inc. - Cambridge MA
International Classification:
C07C 211/00
C09B 11/02
A61K 31/66
US Classification:
564316, 514114
Abstract:
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Heterobicyclic Sphingosine 1-Phosphate Analogs

View page
US Patent:
8349849, Jan 8, 2013
Filed:
Oct 30, 2009
Appl. No.:
12/588882
Inventors:
Richard D. Caldwell - Somerville MA, US
Kevin M. Guckian - Marlborough MA, US
Gnanasambandam Kumaravel - Westford MA, US
Edward Yin-Shiang Lin - Chestnut Hill MA, US
Xiaogao Liu - Dover MA, US
Bin Ma - Arlington MA, US
Daniel M. Scott - Weston MA, US
Zhan Shi - Concord MA, US
Jermaine Thomas - Chelsea MA, US
Arthur G. Taveras - Southborough MA, US
Guo Zhu Zheng - Lexington MA, US
Assignee:
Biogen Idec MA Inc. - Cambridge MA
International Classification:
A61K 31/517
US Classification:
5142661, 544283
Abstract:
Compounds of formula (I):.

Bicyclic Aryl Sphingosine 1-Phosphate Analogs

View page
US Patent:
8546359, Oct 1, 2013
Filed:
Sep 10, 2012
Appl. No.:
13/608227
Inventors:
Richard D. Caldwell - Somerville MA, US
Kevin M. Guckian - Marlborough MA, US
Gnanasambandam Kumaravel - Westford MA, US
Edward Yin-Shiang Lin - Chestnut Hill MA, US
Xiaogao Liu - Dover MA, US
Bin Ma - Arlington MA, US
Daniel M. Scott - Weston MA, US
Zhan Shi - Concord MA, US
Jermaine Thomas - Chelsea MA, US
Arthur G. Taveras - Southborough MA, US
Guo Zhu Zheng - Lexington MA, US
Assignee:
Biogen Idec MA Inc. - Cambridge MA
International Classification:
A01N 57/00
C07C 211/00
US Classification:
514114, 564316
Abstract:
Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors.

Arylphenylamino-,Arylphenylamide-, And Arylphenylether-Sulfide Derivatives

View page
US Patent:
20070259863, Nov 8, 2007
Filed:
Apr 28, 2005
Appl. No.:
11/587732
Inventors:
Donovan Chin - Lexington MA, US
Thomas Durand-Reville - Cambridge MA, US
Francine Farouz - Mercer Island WA, US
Kerry Fowler - Seattle WA, US
Kevin Guckian - Marlborough MA, US
Irina Jaconbson - Sammamish WA, US
Ramesh Kasar - Bellevue WA, US
Russell Petter - Stow MA, US
Daniel Scott - Weston MA, US
C. Gregory Sowell - Mukilteo WA, US
Eugene Thorsett - Kirkland WA, US
Edward Yin-Shiang Lin - Chestnut Hill MA, US
Assignee:
ICOS Corporation - Bothell WA
Biogen Idec MA Inc. - Cambridge MA
International Classification:
C07D 307/54
US Classification:
514228800, 514255060, 544406000, 544063000
Abstract:
The present invention relates in part to compounds of formulas I and III: and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.

Arylphenylamino- And Arylphenylether-Sulfide Derivatives, Useful For The Treatment Of Inflammatory And Immune Diseases, And Pharmaceutical Compositions Containing Them

View page
US Patent:
20080234271, Sep 25, 2008
Filed:
Apr 28, 2005
Appl. No.:
11/579098
Inventors:
Kevin Guckian - Marlborough MA, US
Daniel Scott - Weston MA, US
Irina Jacobson - Sammamish WA, US
Assignee:
ICOS Corporation - Bothell WA
Biogen Idec MA Inc. - Cambridge MA
International Classification:
A61K 31/5377
C07D 413/06
A61P 29/00
US Classification:
5142355, 544152, 5142315, 544131
Abstract:
The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.

Imidazolone Compounds And Methods Of Making And Using The Same

View page
US Patent:
20100035918, Feb 11, 2010
Filed:
Jan 30, 2008
Appl. No.:
12/525106
Inventors:
Kevin Guckian - Marlborough MA, US
Edward Lin - Somerville MA, US
Assignee:
Biogen Idec MA Inc - Cambridge MA
International Classification:
A61K 31/437
C07D 471/02
A61P 35/00
A61P 19/04
A61P 1/00
A61P 25/00
US Classification:
514300, 546117
Abstract:
In one aspect, the invention features a compound of the general Formula (I). Compounds of Formula (I) possess high affinity for Alk 5 and/or AIk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.

Substituted Pyrazalones

View page
US Patent:
20100056505, Mar 4, 2010
Filed:
Nov 21, 2006
Appl. No.:
12/085380
Inventors:
Mary Beth Carter - Lawrence KS, US
Claudio Chuaqui - Arlington MA, US
Kevin Guckian - Marlborough MA, US
Edward Lin - Chesnut Hill MA, US
Michael J. Choi - San Diego CA, US
Zhan Deng - Winchester MA, US
Lihong Sun - Lexington MA, US
International Classification:
A61K 31/498
C07D 403/02
C07D 401/14
C07D 409/14
C07D 403/12
C07D 417/14
C07D 413/14
A61K 31/541
A61K 31/5377
A61P 43/00
A61P 35/00
A61P 9/00
A61P 9/12
US Classification:
5142282, 544353, 544 581, 544116, 514249, 5142348
Abstract:
The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.
Control profile
Kevin M Guckian from Northborough, MA, age ~50 Get Report